Ob(nox)ious fibrosis

Although Esbriet pirfenidone, the only marketed drug for idiopathic pulmonary fibrosis, has shown a mortality benefit, the effects are modest and there remains room for improvement. New preclinical findings suggest that inhibiting NADPH oxidase 4 could both resolve and reverse fibrosis.¹

Based on the results, Genkyotex S.A. plans to advance its GKT137831 NADPH oxidase 4 (NOX4) inhibitor to treat IPF...